Recherche
Publications

Liste complète des publications 2014-2019

Verkarre V, Bibeau F [The inherited cancers, the pathologist]. Ann Pathol. 2020;40(2):61-62. doi:10.1016/j.annpat.2020.02.016

Cohen R, Pudlarz T, Garcia-Larnicol M-L, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]. Bull Cancer. 2020;107(4):438-446. doi:10.1016/j.bulcan.2019.11.016

Latorzeff I, Sargos P, Créhange G, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D [Indications and outlooks of radiohormonal therapy of high-risk prostate cancers]. Cancer Radiother. Feb 11, 2020. doi:10.1016/j.canrad.2019.06.018

Maria A, Bourgier C, Martinaud C, Borie R, Rozier P, Rivière S, Crestani B, Guilpain P [From fibrogenesis towards fibrosis: Pathophysiological mechanisms and clinical presentations]. Rev Med Interne. Feb 08, 2020. doi:10.1016/j.revmed.2020.01.002

Adenis A, Samalin E, Mazard T, Portales F, Mourregot A, Ychou M [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]. Bull Cancer. Jan 21, 2020. doi:10.1016/j.bulcan.2019.12.005

Gros L, Paturel C, Perrot I, Bensussan A, Eliaou J-F, Bastid J, Bonnefoy N [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response]. Med Sci (Paris). 2020;36(2):112-115. doi:10.1051/medsci/2020006

Mazieres J, Cropet C, Montané L, Barlesi F, Souquet P, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Jaffro M, Collot S, Ferretti G, Tiffon C, Mahier-Ait Oukhatar C, Blay J Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann. Oncol.. 2020;31(2):289-294. doi:10.1016/j.annonc.2019.10.022

Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier M, Goncalves A, Dalenc F, Deluche E, Fresnel J, Augereau P, Ferrero J, Geffrelot J, Fumet J-D, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Mouttet-Audouard R, Bachelot T, Courtinard C Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. Eur. J. Cancer. 2020;125. doi:10.1016/j.ejca.2019.11.001

Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget J-P The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2020;34(5):1315-1328. doi:10.1038/s41375-019-0677-4

Alame M, Cornillot E, Cacheux V, Tosato G, Four M, Oliveira L, Gofflot S, Delvenne P, Turtoi E, Cabello-Aguilar S, Nishiyama M, Turtoi A, Martineau V, Colinge J The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. 2020;10(10):4383-4394. doi:10.7150/thno.42986

Bastid J, Dejou C, Docquier A, Bonnefoy N The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer. Front Immunol. 2020;11. doi:10.3389/fimmu.2020.00718

Samalin E, Adenis A TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?. Lancet Oncol.. Jul 16, 2020. doi:10.1016/S1470-2045(20)30337-5

Khashper A, Addley H, Abourokbah N, Nougaret S, Sala E, Reinhold C T2-Hypointense Adnexal Lesions: An Imaging Algorithm. Radiographics. 2020;40(4):1200. doi:10.1148/rg.2020204005

Deshayes E, Piron L, Bouvier A, Lapuyade B, Lermite E, Vervueren L, Laurent C, Pinaquy J-B, Chevallier P, Dohan A, Rode A, Sengel C, Guillot C, Guiu B Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases. BMC Cancer. 2020;20(1):574. doi:10.1186/s12885-020-07065-z

Mangeat T, Gracia M, Martineau P, Robert B Stratégies de ciblage spécifique de la tumeur fondées sur les caractéristiques des antigènes tumoraux et du microenvironnement tumoral. 2020;36.

Samalin E, Fouchardière C, Boige V, Senellart H, Guimbaud R, Galais M-P, Lièvre A, Seitz J-F, Metges J-P, Bouché O, Boissière-Michot F, Lopez-Crapez E, Bibeau F, Ho-Pun-Cheung A, Ychou M, Adenis A, Di Fiore F, Mazard T Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). Clin Colorectal Cancer. May 15, 2020. doi:10.1016/j.clcc.2020.04.008

Glehen O, Guilloit J-M, Bereder J-M, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech J-J, Kianmanesh R, Carretier M, Marchal F, Arvieux C, Brigand C, Meeus P, Rat P, Durand-Fontanier S, Mariani P, Lakkis Z, Loi V, Pirro N, Sabbagh C, Texier M, Elias D Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol.. Jul 24, 2020. doi:10.1016/S1470-2045(20)30322-3

Thierry A SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure. Clin. Sci.. 2020;134(12):1295-1300. doi:10.1042/CS20200531

Heudel P, Delaloge S, Parent D, Madranges N, Levy C, Dalenc F, Brain E, Uwer L, Augereau P, Mailliez A, Perrin C, Sablin M-P, Mouret-Reynier M-A, Vermeulin T, Eymard J-C, Petit T, Ferrero J-M, Ilie S, Goncalves A, Chenuc G, Robain M Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study. Anticancer Res.. 2020;40(7):3905-3913. doi:10.21873/anticanres.14381

Ghoroghi S, Mary B, Larnicol A, Klein A, Osmani N, Busnelli I, Delalande F, Paul N, Halary S, Gros F, Fouillen L, Haeberle A, Royer C, Spiegelhalter C, André-Grégoire G, Murphy K, Timpson P, Carapito R, Blot-Chabaud M, Gavard J, Carapito C, Vitale N, Lefebvre O, Goetz J, Hyenne V Ral GTPases promote metastasis by controlling biogenesis and organ colonization of exosomes. January 1, 2020. doi:10.1101/2020.07.10.196691

Nougaret S, Monsonis B, Molinari N, Piron L, Kassam Z, Cassinotto C, Guiu B Quantification of liver fat content in liver and primary liver lesions using triple-echo-gradient-echo MRI. Eur Radiol. 2020-4-22. doi:10.1007/s00330-020-06757-1

Hamyeh M, Bernex F, Larive R, Naldi A, Urbach S, Simony-Lafontaine J, Puech C, Bakhache W, Coopman P, Hendriks W, Freiss G PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. Theranostics. 2020;10(3):1016-1032. doi:10.7150/thno.38537

Hamyeh M, Bernex F, Larive R, Naldi A, Urbach S, Simony-Lafontaine J, Puech C, Bakhache W, Solassol J, Coopman P, Hendriks W, Freiss G PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. 2020.

Sarrabay G, Méchin D, Salhi A, Boursier G, Rittore C, Crow Y, Rice G, Tran T-A, Cezar R, Duffy D, Bondet V, Boudhane L, Broca C, Kant B, VanGijn M, Grandemange S, Richard E, Apparailly F, Touitou I PSMB10, the last immunoproteasome gene missing for PRAAS. J. Allergy Clin. Immunol.. 2020;145(3):1015-1017.e6. doi:10.1016/j.jaci.2019.11.024

Delattre J-F, Cohen R, Henriques J, Falcoz A, Emile J-F, Fratte S, Chibaudel B, Dauba J, Dupuis O, Bécouarn Y, Bibeau F, Taieb J, Louvet C, Vernerey D, André T, Svrcek M Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). JCO. 2020-03-13. doi:10.1200/JCO.19.01960



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés